Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2023-01-12 4:31 pm Sale | 13D | IMAGO BIOSCIENCES INC IMGO | Clarus Lifesciences III L.P. | 0 0% | -2,436,732 (Position Closed) | View |
| 2022-04-01 5:18 pm Sale | 13D | IMAGO BIOSCIENCES INC IMGO | Clarus Lifesciences III L.P. | 2,436,732 7.2% | -938,305 (-27.80%) | View |
| 2022-01-12 4:30 pm Sale | 13D | ESSA PHARMA INC EPIX | Clarus Lifesciences III L.P. | 2,187,912 4.96% | -1,291,202 (-37.11%) | View |
| 2021-07-30 4:32 pm Purchase | 13D | IMAGO BIOSCIENCES INC IMGO | Clarus Lifesciences III L.P. | 3,375,037 10.5% | 3,375,037 (New Position) | View |
| 2020-07-09 4:48 pm Sale | 13D | ENTASIS THERAPEUTICS HLDGS INC ETTX | Clarus Lifesciences III L.P. | 1,339,836 4.9% | -283,569 (-17.47%) | View |
| 2020-05-01 5:01 pm Unchanged | 13D | ENTASIS THERAPEUTICS HLDGS INC ETTX | Clarus Lifesciences III L.P. | 1,623,405 11.1% | 0 (Unchanged) | View |
| 2019-09-06 5:22 pm Purchase | 13D | ESSA PHARMA INC EPIX | Clarus Lifesciences III L.P. | 3,479,114 16.7% | 1,704,493 (+96.05%) | View |
| 2019-08-05 6:52 pm Sale | 13D | AVROBIO INC AVRO | Clarus Lifesciences III L.P. | 0 0% | -1,481,162 (Position Closed) | View |
| 2019-05-22 9:13 pm Sale | 13D | AVROBIO INC AVRO | Clarus Lifesciences III L.P. | 1,481,162 6.1% | -1,481,163 (-50.00%) | View |